Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Nevro revenue
Nevro's revenue is $408.5 million.
What is Nevro's revenue?
- Nevro's revenue growth from 2013 to 2024 is 1,638.37%.
- Nevro has 804 employees, and the revenue per employee ratio is $508,106.
- Nevro's peak quarterly revenue was $116.2M in 2023(q4).
- Nevro peak revenue was $425.2M in 2023.
- Nevro annual revenue for 2023 was 425.2M, 4.63% growth from 2022.
- Nevro annual revenue for 2024 was 408.5M, -3.92% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Nevro historical revenue
Nevro's peak revenue was $425.2M in 2023. The peak quarterly revenue was $116.2M in 2023(q4).
Nevro's revenue increased from $23.5m in 2013 to $408.5M currently. That's a 1,638.37% change in annual revenue.
Nevro annual revenue
Nevro annual revenue over time
| Fiscal year / year | Nevro revenue |
|---|---|
| 2013 | $23.5M |
| 2014 | $32.6M |
| 2015 | $69.6M |
| 2016 | $228.5M |
| 2017 | $326.7M |
| 2018 | $387.3M |
| 2019 | $390.3M |
| 2020 | $362.0M |
| 2021 | $386.9M |
| 2022 | $406.4M |
| 2023 | $425.2M |
| 2024 | $408.5M |
Rate Nevro's financial transparency
Nevro annual growth
Nevro saw the greatest revenue growth in 2016, when revenue increased by 228.28%.
Nevro had the lowest revenue growth in 2020, when revenue changed by -7.23%.
Nevro annual growth rate over time
| Year | Nevro growth |
|---|---|
| 2014 | 39%↑ |
| 2015 | 114%↑ |
| 2016 | 228%↑ |
| 2017 | 43%↑ |
| 2018 | 19%↑ |
| 2019 | 1%↑ |
| 2020 | -7%↓ |
| 2021 | 7%↑ |
| 2022 | 5%↑ |
| 2023 | 5%↑ |
| 2024 | -4%↓ |
Nevro quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Nevro quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2014 | - | - | $8.7M | $9.7M |
| 2015 | $9.7M | $11.4M | $15.4M | $33.1M |
| 2016 | $41.7M | $55.4M | $60.9M | $70.5M |
| 2017 | $68.4M | $78.0M | $82.3M | $98.0M |
| 2018 | $87.6M | $96.1M | $95.6M | $107.9M |
| 2019 | $82.1M | $93.6M | $100.2M | $114.4M |
| 2020 | $87.5M | $56.4M | $108.5M | $109.7M |
| 2021 | $88.6M | $102.3M | $93.2M | $102.8M |
| 2022 | $87.8M | $104.2M | $100.5M | $113.8M |
| 2023 | $96.3M | $108.8M | $103.9M | $116.2M |
| 2024 | $101.9M | $104.2M | $96.9M | $105.5M |
Nevro jobs nearby
Do you work at Nevro?
Is Nevro transparent about its revenue structure?
Nevro financial information
| CEO | D. Keith Grossman |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 804 |
| Date Founded | 2006 |
| Headquarters | Redwood City, California |
| Number of Locations | 1 |
| Revenue | $408.5M |
| Net Income | $3,001,000 |
| Gross Proft | $269.5M (2024) |
| EBITDA | ($95.8M) (2024) |
| PE Ratio | -12.76 |
| Tax Rate | -0.0% |
| Market Capitalization | $1.4B |
| Total Assets | $602,408,000 |
| Ticker | NVRO |
Nevro jobs you might like
Nevro financing
Nevro received early financing of $5.5M on 2006-12-04.
| Series | Round size | Date |
|---|---|---|
| Seed | $5.5M | 12/2006 |
| Series A | $21.8M | 09/2008 |
| Series B | $58M | 07/2011 |
| Series C | $48M | 03/2013 |
| Debt Financing | $50M | 12/2014 |
| Post Ipo Debt | $172.5M | 06/2016 |
Nevro investors
| Investors | Security type |
|---|---|
| Venturi Group | Seed |
| Bay City Capital | Seed |
| MPM Capital | Seed |
| Aberdare Ventures | Seed |
| Mayo Clinic | Seed |
| Three Arch Partners | Seed |
| Bay City Capital | Series A |
| MPM Capital | Series A |
| Aberdare Ventures | Series A |
| Mayo Clinic | Series A |
| Accuitive Medical Ventures | Series A |
| Three Arch Partners | Series A |
| Johnson & Johnson Development Corporation | Series B |
| Bay City Capital | Series B |
| MPM Capital | Series B |
| Aberdare Ventures | Series B |
| Mayo Clinic | Series B |
| Three Arch Partners | Series B |
| Accuitive Medical Ventures | Series B |
| Johnson & Johnson Development Corporation | Series C |
| Bay City Capital | Series C |
| Novo Ventures | Series C |
| New Enterprise Associates (NEA) | Series C |
| Covidien Ventures | Series C |
| MPM Capital | Series C |
| Mayo Clinic | Series C |
| Three Arch Partners | Series C |
| Accuitive Medical Ventures | Series C |
| CRG LP | Debt Financing |
Nevro competitors
Nevro's top competitor, Medtronic, earned an annual revenue of $17.0B.
Nevro's smallest competitor is CAS Medical Systems with revenue of $21.9M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Medtronic | $73,671 | $17.0B | 104,950 | 1,859 |
| Nuvectra | $45,638 | $50.9M | 197 | - |
| CAS Medical Systems | $51,141 | $21.9M | 73 | - |
| Access Closure | $55,268 | $54.2M | 200 | - |
| Mead Johnson & Company LLC | $68,577 | $3.7B | 7,500 | - |
| Genentech | $97,473 | $166.9M | 13,638 | 469 |
| Centocor | $73,664 | $110.0M | 3,000 | - |
| Sientra | $51,621 | $90.5M | 259 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Nevro highest paying jobs
Zippia gives an in-depth look into the details of Nevro, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Nevro. The employee data is based on information from people who have self-reported their past or current employments at Nevro. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Nevro. The data presented on this page does not represent the view of Nevro and its employees or that of Zippia.
Nevro may also be known as or be related to NEVRO CORP, Nevro, Nevro Corp, Nevro Corp. and Nevro Corporation.